Opaleye Management’s Neos Therapeutics, Inc NEOS Stock Holding History

Opaleye Management’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$365K	–	44
2017 Q2	$365K	Buy	+50,000	New	+$378K	0.15%	40

Other funds holding NEOS

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

CAM

Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management's NEOS Position: Q3 2017 in Review

Opaleye Management sold out of Neos Therapeutics, Inc (NEOS) in Q3 2017, closing a stake of 50,000 shares — an estimated $365K sold.

Opaleye Management first reported a position in NEOS in Q2 2017 and held it in 1 quarter. The position peaked at $365K in Q2 2017. 63 funds tracked by Wall St. Rank hold NEOS as of Q3 2017.

Opaleye Management reported no remaining Neos Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
Opaleye Management sold 50,000 Neos Therapeutics, Inc shares in Q3 2017, an estimated $365K.
Opaleye Management first reported a position in Neos Therapeutics, Inc in Q2 2017 and held it in 1 quarter.
Opaleye Management's Neos Therapeutics, Inc position peaked at $365K in Q2 2017.
63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2017.

Based on Opaleye Management's 13F filing for Q3 2017, filed 14 Nov 2017.